Introduction

Joint wear, particularly in the knee, is widespread and can cause persistent pain that affects everyday activities. If you are weighing up a non-surgical option for cartilage support, this article explains what ChondroFiller is, how it is given, and what the evidence currently shows — with realistic expectations throughout.

What Is ChondroFiller?

ChondroFiller is a CE-marked (Class III medical device) injectable, cell-free collagen scaffold made by Meidrix Biomedicals in Germany and imported into the UK under prescription. It is composed of type I collagen that self-gels within approximately three to five minutes once placed in the joint. Because it contains no transplanted cells, it works by recruiting the patient's own progenitor cells from the surrounding tissue and subchondral bone into the scaffold, where they can differentiate and begin to lay down new cartilage matrix. The device is not a drug; it is an acellular biological scaffold, and the CE marking along with the published clinical evidence relates to ChondroFiller as a device.

Why Non-Surgical Options Matter

Cartilage has a limited intrinsic capacity for self-repair, so treatment can be challenging. Physiotherapy and anti-inflammatory medication address symptoms rather than the underlying tissue deficit. Surgical options — including keyhole procedures — involve a theatre setting, anaesthetic, and structured recovery. A non-surgical injection that aims to support the joint is therefore of genuine clinical interest, particularly for patients with accessible lesions, smaller joints, or those for whom surgery is not yet appropriate.

ChondroFiller is best understood as a supportive, joint-preserving injection with biological potential, not as a cure or a means of reversing established arthritis. It is distinct from the Liquid Cartilage surgical protocol, which is a separate keyhole (arthroscopic) procedure used for larger or load-bearing defects and which combines the ChondroFiller scaffold with biological adjuncts and, where indicated, the patient's own stem cells.

How the ChondroFiller Injection Is Given

The ChondroFiller injection is a minimally invasive, outpatient procedure. It is delivered under ultrasound guidance directly into the joint. There is no operation, no incision, and no general anaesthetic. A consultation beforehand confirms whether you are a suitable candidate, taking into account the size and location of the cartilage defect, your activity level, age, overall health, and the degree of joint wear. Most patients return to normal activities promptly, though individual recovery varies.

What the Evidence Shows

Published clinical series and the manufacturer's clinical evaluation data indicate meaningful improvements in patient-reported outcomes. In knee studies, International Knee Documentation Committee (IKDC) scores have improved by approximately 30 points over 12 to 36 months. In hip applications, modified Harris Hip Score (mHHS) improvements of more than 30 points have been reported. MRI assessment of repair tissue quality, measured using MOCART scoring, has reached around 80 and above in published series. A study of ChondroFiller in trapeziometacarpal (thumb base) osteoarthritis also demonstrated significant pain reduction and functional improvement. The device has been used across more than 19,000 units with no serious adverse incidents reported to date.

These figures come from manufacturer-sponsored investigations and independent literature and should be interpreted with appropriate caution. Not every patient achieves similar results, and ChondroFiller is not indicated for every type or stage of cartilage damage.

Reference: Corain M, Zanotti F, Giardini M, Gasperotti L, Invernizzi E, Biasi V, Lavagnolo U. The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage. 2023.

Who Might Consider the ChondroFiller Injection?

It may be appropriate for people with osteoarthritis or focal cartilage wear who want a less invasive option and whose defect is accessible to injection. Suitability depends on individual clinical factors, including the size of the defect (the device is designed for defects up to around 6 cm²), joint involved, and overall health. Benefits cannot be guaranteed, and some patients will require a surgical approach — such as the Liquid Cartilage protocol — for more complex or larger lesions.

Conclusion

ChondroFiller is a non-surgical, injectable, cell-free collagen therapy that may help support a worn joint and ease symptoms for some people. It is a CE-marked device with a growing evidence base, but it is vital to seek individual professional advice before proceeding. At the London Cartilage Clinic, a specialist assessment will establish whether the ChondroFiller injection, a surgical approach, or another pathway best suits your situation.